Processing...
Clinical Trials for Melanoma
Search
Search
There are 169 active trials for advanced/metastatic melanoma.
Click on a trial to see more information.
169 trials meet filter criteria.
Sort by:
TrialFetch AI summary: Previously untreated adults with unresectable or metastatic cutaneous melanoma (AJCC IIIC–IV, ECOG 0–1) are randomized to pembrolizumab alone versus pembrolizumab plus lifileucel, an autologous tumor-infiltrating lymphocyte therapy infused after lymphodepleting chemotherapy (with post-infusion IL-2) that provides polyclonal tumor‑reactive T cells to augment antitumor cytotoxicity; crossover to lifileucel is allowed at BICR-confirmed progression. Excludes uveal melanoma and symptomatic untreated brain mets; prior adjuvant/neoadjuvant PD‑1/CTLA‑4/BRAF±MEK allowed if completed ≥6 months before metastatic progression.
ClinicalTrials.gov ID: NCT05727904
TrialFetch AI summary: Adults with metastatic cutaneous melanoma, including those refractory to prior PD-1/PD-L1 therapy and with at least one resectable lesion for TIL harvest, receive non-myeloablative lymphodepletion followed by autologous TIL infusion and high-dose IL-2, with most eligible patients also receiving pembrolizumab (anti–PD-1) given peri- and post-infusion. Patients with controlled small asymptomatic brain metastases may enroll; key exclusions include significant autoimmune disease, active infections, major cardiopulmonary compromise, and prior severe immune-related toxicities to PD-1/PD-L1 agents for the pembrolizumab arm.
ClinicalTrials.gov ID: NCT02621021
TrialFetch AI summary: Adults with unresectable stage III–IV cutaneous melanoma (non-uveal), treatment-naïve for metastatic disease, receive ipilimumab plus fixed-dose nivolumab/relatlimab with added sarilumab, an interleukin‑6 receptor–blocking antibody intended to mitigate immune-related toxicity and potentially enhance efficacy. Excludes active/untreated brain metastases, active autoimmune disease requiring systemic therapy, and significant immunosuppression.
ClinicalTrials.gov ID: NCT05428007
TrialFetch AI summary: Adults with measurable advanced solid tumors that have progressed after standard therapy or lack a standard treatment option receive a single intravenous infusion of IDOV-Immune. This engineered oncolytic vaccinia virus is designed to replicate preferentially in tumor cells, destroy them, and stimulate antitumor immunity.
ClinicalTrials.gov ID: NCT06910657
TrialFetch AI summary: Adults with locally advanced or metastatic solid tumors who lack effective standard treatment receive intravenous JMT108, initially every 2 weeks, in dose-escalation and tumor-specific expansion cohorts. JMT108 is an investigational PD-1–targeted antibody–IL-15 fusion protein designed to block PD-1 and deliver IL-15 signaling preferentially to PD-1–positive immune cells.
ClinicalTrials.gov ID: NCT07317505
TrialFetch AI summary: Adults with measurable metastatic uveal melanoma receive oral NBM-BMX, an investigational HDAC8 inhibitor, twice daily. HLA-A*02:01-positive patients generally must have received tebentafusp, and patients previously treated with an HDAC inhibitor are excluded.
ClinicalTrials.gov ID: NCT07136181
TrialFetch AI summary: Adults with unresectable or metastatic melanoma progressing after anti-PD-1–containing therapy receive personalized DOC1021 (dubodencel) dendritic-cell immunotherapy plus peginterferon alfa-2a. DOC1021 uses the patient’s dendritic cells loaded with autologous tumor lysate and tumor-derived mRNA to stimulate antitumor T-cell responses; anti-PD-1 therapy may be resumed later.
ClinicalTrials.gov ID: NCT07288112
TrialFetch AI summary: Adults with metastatic or unresectable locally advanced NSCLC, esophageal squamous cell carcinoma, or cutaneous melanoma after standard therapy or 1–2 prior systemic regimens receive IV PF-08046033 in 21-day cycles. PF-08046033 is an investigational GPNMB-directed antibody-drug conjugate delivering auristatin S to GPNMB-expressing tumor cells, with dose escalation followed by tumor-specific expansion cohorts.
ClinicalTrials.gov ID: NCT07519655
TrialFetch AI summary: Adults with advanced measurable solid tumors who have exhausted or are ineligible for standard therapies, with a melanoma-focused expansion requiring known BRAF status and generally ≤3 prior systemic lines. All patients receive BI 3810944 monotherapy, an investigational small-molecule anticancer agent with undisclosed target/mechanism, given initially weekly then typically every 3 weeks.
ClinicalTrials.gov ID: NCT07224425
TrialFetch AI summary: Adults with refractory unresectable or metastatic solid tumors and an accessible injectable lesion, with expansion cohorts in cutaneous squamous-cell carcinoma, melanoma, head and neck squamous-cell carcinoma, NSCLC, and triple-negative breast cancer. Patients receive intratumoral N17350 every 2 weeks, a recombinant mutant porcine pancreatic elastase targeting the neutrophil elastase/ELANE pathway and designed to induce immunogenic tumor-cell death.
ClinicalTrials.gov ID: NCT07339176